Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

Target Oncol · 2023 · PMC10518021 · PMID 37713090

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

However, a decreasing trend in the incidence of anemia was observed, with a highest rate observed in the lowest quartile group.

also in 47,180 other papers

showed a trendno p-value reported

Responders to teclistamab also showed a trend of sBCMA reduction over time.

also in 53,322 other papers

a positive trendno p-value reported

The exposure–response analyses for ORR showed a positive trend with increasing teclistamab systemic exposure, with a plateau at the RP2D, and there was no apparent exposure–response trend for safety or other efficacy endpoints.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.